Reference health
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
1 of 31 checkable references need attention · checked 2026-08-02
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1210/jc.87.6.2784
The 30 checked references that resolve
resolves10.1056/NEJM199309303291401
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
resolves10.1016/0168-8227(95)01064-K
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
resolves10.1016/S0140-6736(98)07019-6
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
resolves10.2337/diabetes.44.11.1249
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group
resolves10.1001/jama.281.21.2005
Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>
resolves10.2337/diacare.27.1.17
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
resolves10.2337/diabetes.51.9.2796
Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
resolves10.2337/diabetes.54.4.1150
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
resolves10.1016/S0140-6736(06)69420-8
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
resolves10.1210/jc.82.7.2108
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome
resolves10.1111/j.1464-5491.2006.02022.x
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
resolves10.2337/diacare.21.1.23
Evaluation of a Self-Administered Sensory Testing Tool to Identify Patients at Risk of Diabetes-Related Foot Problems
resolves10.2337/dc06-9912
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
resolves10.1016/S0140-6736(98)07037-8
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
resolves10.1172/JCI7231
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
resolves10.2337/diabetes.51.7.2170
β-Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U.S.
resolves10.2337/diabetes.55.04.06.db05-1100
The Natural Course of β-Cell Function in Nondiabetic and Diabetic Individuals
resolves10.1038/oby.2002.137
Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients
resolves10.2337/diabetes.50.9.2094
PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein
resolves10.1161/01.ATV.0000200136.56716.30
Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome
resolves10.1503/cmaj.050748
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
resolves10.1097/00045391-200603000-00009
Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs
resolves10.1161/01.CIR.0000103683.99399.7E
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
resolves10.1016/S0140-6736(05)67528-9
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
The 1 reference without a DOI — listed, not checked
no DOI — not checkedr018
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-02 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1056/nejmoa066224"><img src="https://citestamp.com/citestamped/10.1056/nejmoa066224/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1056/nejmoa066224)